Tirzepatide has emerged as a groundbreaking treatment for type 2 diabetes, offering promising outcomes. However, the cost of this innovative drug and its availability have become key issues for patients and healthcare practitioners. While tirzepatide has been authorized by regulatory agencies, its costly nature presents a significant barrier to ma